[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fLTg_3w5Od12gRNo1n3eqRdYZULr_7ah6HFKYtD0IPRY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":44,"rows":51},"Damanhour University",[4],75,false,4,1,9216,2,28,[14,17,20,23,25,27,29,31],{"name":15,"count":16},"Breast Cancer",6,{"name":18,"count":19},"Heart Failure",5,{"name":21,"count":22},"Coronary Artery Disease",3,{"name":24,"count":22},"Healthy",{"name":26,"count":22},"Healthy Normotensive Participants",{"name":28,"count":11},"Ventilator Associated Pneumonia",{"name":30,"count":11},"Chemotherapeutic Toxicity",{"name":32,"count":11},"Type 2 Diabetes",[34,39],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06813222","Anemia-Related Outcomes in Patients With CKD Treated With Dapagliflozin","2025-03-01","Dapagliflozin",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT07081399","the Effect of Adult Intubated Patient Clinical Pathway on Post-extubation Complications Prevention","2025-03-08","ETT cuff pressure monitoring, ETT suctioning, cough augmentation technique, swallowing exercises,: Nebulized budesonide 1mg and IV methylprednisolone 40 mg we",[45,46,47,48,49,50],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[52,77,100,127,154,181,199,224,249,276,294,319,337,364,382,408,442,466,493,511,535,559,582,608,626,652,677,704,722,773,819,849,875,908,930,952,982,1006,1030,1055,1073,1098,1123,1146,1164,1182,1200,1225,1243,1261,1288,1306,1329,1347,1365,1390,1413,1437,1455,1477],{"intervention":43,"totalTrials":9,"cells":53},{"EARLY_PHASE1":54,"PHASE1":66,"PHASE2":69,"PHASE3":71,"PHASE4":73,"NA":75},{"trials":55,"activeCount":9,"soonestReadout":42},[56],{"nctId":40,"briefTitle":41,"status":57,"phases":58,"primaryCompletion":42,"completion":59,"start":60,"enrollment":61,"conditions":62,"interventions":65},"RECRUITING",[45],"2025-08","2024-08-08",80,[63,64],"Dysphagia","Dysphagia Rehabilitation",[43],{"trials":67,"activeCount":68},[],0,{"trials":70,"activeCount":68},[],{"trials":72,"activeCount":68},[],{"trials":74,"activeCount":68},[],{"trials":76,"activeCount":68},[],{"intervention":38,"totalTrials":9,"cells":78},{"EARLY_PHASE1":79,"PHASE1":81,"PHASE2":83,"PHASE3":85,"PHASE4":87,"NA":89},{"trials":80,"activeCount":68},[],{"trials":82,"activeCount":68},[],{"trials":84,"activeCount":68},[],{"trials":86,"activeCount":68},[],{"trials":88,"activeCount":68},[],{"trials":90,"activeCount":9,"soonestReadout":37},[91],{"nctId":35,"briefTitle":36,"status":92,"phases":93,"primaryCompletion":37,"completion":37,"start":94,"enrollment":95,"conditions":96,"interventions":99},"ACTIVE_NOT_RECRUITING",[],"2021-04-01",100,[97,98],"Anemia","CKD",[38],{"intervention":101,"totalTrials":9,"cells":102},"Doxycycline 100 MG Oral",{"EARLY_PHASE1":103,"PHASE1":105,"PHASE2":107,"PHASE3":109,"PHASE4":111,"NA":125},{"trials":104,"activeCount":68},[],{"trials":106,"activeCount":68},[],{"trials":108,"activeCount":68},[],{"trials":110,"activeCount":68},[],{"trials":112,"activeCount":68},[113],{"nctId":114,"briefTitle":115,"status":116,"phases":117,"primaryCompletion":118,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":124},"NCT04239755","Doxycycline in Acute Traumatic Brain Injury","COMPLETED",[49],"2020-07-30","2020-10-30","2020-02-01",50,[123],"Traumatic Brain Injury",[101],{"trials":126,"activeCount":68},[],{"intervention":128,"totalTrials":9,"cells":129},"amlodipine (10 mg\u002Fd).",{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":136,"PHASE4":138,"NA":152},{"trials":131,"activeCount":68},[],{"trials":133,"activeCount":68},[],{"trials":135,"activeCount":68},[],{"trials":137,"activeCount":68},[],{"trials":139,"activeCount":68},[140],{"nctId":141,"briefTitle":142,"status":116,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":150},"NCT03990480","Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Level",[49],"2019-04-01","2019-04-10","2018-12-01",230,[149],"Hypertension",[151,128],"valsartan",{"trials":153,"activeCount":68},[],{"intervention":155,"totalTrials":9,"cells":156},"Metformin 1000 mg Oral",{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":179},{"trials":158,"activeCount":68},[],{"trials":160,"activeCount":68},[],{"trials":162,"activeCount":68},[],{"trials":164,"activeCount":68},[],{"trials":166,"activeCount":68},[167],{"nctId":168,"briefTitle":169,"status":116,"phases":170,"primaryCompletion":171,"completion":172,"start":173,"enrollment":61,"conditions":174,"interventions":176},"NCT03693560","Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD",[49],"2019-09-10","2019-10-10","2018-10-08",[21,175],"Diabetes Mellitus, Type 2",[177,155,178],"Vildagliptin 50 mg Oral","Glimepiride upto 4 mg Oral",{"trials":180,"activeCount":68},[],{"intervention":178,"totalTrials":9,"cells":182},{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":189,"PHASE4":191,"NA":197},{"trials":184,"activeCount":68},[],{"trials":186,"activeCount":68},[],{"trials":188,"activeCount":68},[],{"trials":190,"activeCount":68},[],{"trials":192,"activeCount":68},[193],{"nctId":168,"briefTitle":169,"status":116,"phases":194,"primaryCompletion":171,"completion":172,"start":173,"enrollment":61,"conditions":195,"interventions":196},[49],[21,175],[177,155,178],{"trials":198,"activeCount":68},[],{"intervention":200,"totalTrials":9,"cells":201},"Metformin Retard 850 mg",{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":208,"PHASE4":210,"NA":222},{"trials":203,"activeCount":68},[],{"trials":205,"activeCount":68},[],{"trials":207,"activeCount":68},[],{"trials":209,"activeCount":68},[],{"trials":211,"activeCount":68},[212],{"nctId":213,"briefTitle":214,"status":116,"phases":215,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":221},"NCT03845153","Metformin Effect on Fracture Healing in Post-Menopausal Women",[49],"2021-01-01","2019-01-01",40,[220],"Bone Fracture",[200],{"trials":223,"activeCount":68},[],{"intervention":225,"totalTrials":9,"cells":226},"Amantadine (100mg) as add on therapy.",{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":235,"NA":247},{"trials":228,"activeCount":68},[],{"trials":230,"activeCount":68},[],{"trials":232,"activeCount":68},[],{"trials":234,"activeCount":68},[],{"trials":236,"activeCount":68},[237],{"nctId":238,"briefTitle":239,"status":116,"phases":240,"primaryCompletion":241,"completion":242,"start":243,"enrollment":121,"conditions":244,"interventions":246},"NCT04527289","Impact of Amantadine on Traumatic Brain Injury",[49],"2021-10-01","2021-10-30","2020-09-30",[245],"Trauma, Brain",[225],{"trials":248,"activeCount":68},[],{"intervention":250,"totalTrials":9,"cells":251},"Atorvastatin 40 Mg Oral",{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":258,"PHASE4":260,"NA":274},{"trials":253,"activeCount":68},[],{"trials":255,"activeCount":68},[],{"trials":257,"activeCount":68},[],{"trials":259,"activeCount":68},[],{"trials":261,"activeCount":68},[262],{"nctId":263,"briefTitle":264,"status":116,"phases":265,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":272},"NCT03784703","Type 2 Diabetic Patients Maintained on Statin Therapy",[49],"2020-01-30","2020-01-31","2018-01-01",160,[271],"Dyslipidemia Associated With Type II Diabetes Mellitus",[250,273],"Rosuvastatin 10 Mg Oral",{"trials":275,"activeCount":68},[],{"intervention":273,"totalTrials":9,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":286,"NA":292},{"trials":279,"activeCount":68},[],{"trials":281,"activeCount":68},[],{"trials":283,"activeCount":68},[],{"trials":285,"activeCount":68},[],{"trials":287,"activeCount":68},[288],{"nctId":263,"briefTitle":264,"status":116,"phases":289,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":290,"interventions":291},[49],[271],[250,273],{"trials":293,"activeCount":68},[],{"intervention":295,"totalTrials":9,"cells":296},"Sacubitril \u002F Valsartan Oral",{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":305,"NA":317},{"trials":298,"activeCount":68},[],{"trials":300,"activeCount":68},[],{"trials":302,"activeCount":68},[],{"trials":304,"activeCount":68},[],{"trials":306,"activeCount":68},[307],{"nctId":308,"briefTitle":309,"status":116,"phases":310,"primaryCompletion":311,"completion":312,"start":313,"enrollment":61,"conditions":314,"interventions":315},"NCT05881720","Sacubitril\u002FValsartan Versus Valsartan in Heart Failure",[49],"2023-06-18","2023-06-19","2022-01-01",[18],[295,316],"Valsartan 80 mg",{"trials":318,"activeCount":68},[],{"intervention":316,"totalTrials":9,"cells":320},{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":329,"NA":335},{"trials":322,"activeCount":68},[],{"trials":324,"activeCount":68},[],{"trials":326,"activeCount":68},[],{"trials":328,"activeCount":68},[],{"trials":330,"activeCount":68},[331],{"nctId":308,"briefTitle":309,"status":116,"phases":332,"primaryCompletion":311,"completion":312,"start":313,"enrollment":61,"conditions":333,"interventions":334},[49],[18],[295,316],{"trials":336,"activeCount":68},[],{"intervention":338,"totalTrials":9,"cells":339},"Ivabradine Oral",{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":362},{"trials":341,"activeCount":68},[],{"trials":343,"activeCount":68},[],{"trials":345,"activeCount":68},[],{"trials":347,"activeCount":68},[],{"trials":349,"activeCount":68},[350],{"nctId":351,"briefTitle":352,"status":116,"phases":353,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":360},"NCT04448899","Ivabradine in Patients With Congestive Heart Failure",[49],"2021-02-01","2021-02-05","2020-06-01",60,[359],"Congestive Heart Failure",[338,361],"Blacebo plus standard treatment",{"trials":363,"activeCount":68},[],{"intervention":361,"totalTrials":9,"cells":365},{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":380},{"trials":367,"activeCount":68},[],{"trials":369,"activeCount":68},[],{"trials":371,"activeCount":68},[],{"trials":373,"activeCount":68},[],{"trials":375,"activeCount":68},[376],{"nctId":351,"briefTitle":352,"status":116,"phases":377,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":378,"interventions":379},[49],[359],[338,361],{"trials":381,"activeCount":68},[],{"intervention":383,"totalTrials":9,"cells":384},"Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam",{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":389,"PHASE3":391,"PHASE4":404,"NA":406},{"trials":386,"activeCount":68},[],{"trials":388,"activeCount":68},[],{"trials":390,"activeCount":68},[],{"trials":392,"activeCount":68},[393],{"nctId":394,"briefTitle":395,"status":396,"phases":397,"primaryCompletion":398,"completion":399,"start":400,"enrollment":121,"conditions":401,"interventions":403},"NCT05346666","Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus.","UNKNOWN",[48],"2023-09-20","2023-10-20","2022-06-25",[402],"Epilepsy",[383],{"trials":405,"activeCount":68},[],{"trials":407,"activeCount":68},[],{"intervention":409,"totalTrials":11,"cells":410},"Bisoprolol Fumarate",{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":436,"PHASE4":438,"NA":440},{"trials":412,"activeCount":68},[],{"trials":414,"activeCount":68},[],{"trials":416,"activeCount":68},[417,428],{"nctId":418,"briefTitle":419,"status":116,"phases":420,"primaryCompletion":421,"completion":422,"start":423,"enrollment":424,"conditions":425,"interventions":427},"NCT05536271","Pharmacogenetic Study of Bisoprolol in Egyptian Patients With Acute Coronary Syndrome",[47],"2022-06-01","2022-08-16","2021-09-01",127,[426],"Acute Coronary Syndrome",[409],{"nctId":429,"briefTitle":430,"status":116,"phases":431,"primaryCompletion":432,"completion":422,"start":423,"enrollment":433,"conditions":434,"interventions":435},"NCT05536284","Potential Drug Interactions With Bisoprolol in Egyptian Patients With ACS",[47],"2022-05-20",128,[426],[409],{"trials":437,"activeCount":68},[],{"trials":439,"activeCount":68},[],{"trials":441,"activeCount":68},[],{"intervention":443,"totalTrials":9,"cells":444},"Vitamin D",{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":460,"PHASE4":462,"NA":464},{"trials":446,"activeCount":68},[],{"trials":448,"activeCount":68},[],{"trials":450,"activeCount":68},[451],{"nctId":452,"briefTitle":453,"status":116,"phases":454,"primaryCompletion":455,"completion":456,"start":457,"enrollment":95,"conditions":458,"interventions":459},"NCT04166253","Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin",[47],"2020-04-01","2020-05-01","2019-09-01",[15],[443],{"trials":461,"activeCount":68},[],{"trials":463,"activeCount":68},[],{"trials":465,"activeCount":68},[],{"intervention":467,"totalTrials":9,"cells":468},"Metformin Hydrochloride 850 mg",{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":487,"PHASE4":489,"NA":491},{"trials":470,"activeCount":68},[],{"trials":472,"activeCount":68},[],{"trials":474,"activeCount":68},[475],{"nctId":476,"briefTitle":477,"status":116,"phases":478,"primaryCompletion":479,"completion":480,"start":481,"enrollment":482,"conditions":483,"interventions":485},"NCT04170465","Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO)",[47],"2022-04-02","2022-06-28","2019-10-29",70,[484],"Breast Cancer Female",[467,486],"AC-T chemotherapy regimen",{"trials":488,"activeCount":68},[],{"trials":490,"activeCount":68},[],{"trials":492,"activeCount":68},[],{"intervention":486,"totalTrials":9,"cells":494},{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":499,"PHASE3":505,"PHASE4":507,"NA":509},{"trials":496,"activeCount":68},[],{"trials":498,"activeCount":68},[],{"trials":500,"activeCount":68},[501],{"nctId":476,"briefTitle":477,"status":116,"phases":502,"primaryCompletion":479,"completion":480,"start":481,"enrollment":482,"conditions":503,"interventions":504},[47],[484],[467,486],{"trials":506,"activeCount":68},[],{"trials":508,"activeCount":68},[],{"trials":510,"activeCount":68},[],{"intervention":512,"totalTrials":9,"cells":513},"Coenzyme Q10 200mg twice daily",{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":529,"PHASE4":531,"NA":533},{"trials":515,"activeCount":68},[],{"trials":517,"activeCount":68},[],{"trials":519,"activeCount":68},[520],{"nctId":521,"briefTitle":522,"status":116,"phases":523,"primaryCompletion":524,"completion":525,"start":526,"enrollment":218,"conditions":527,"interventions":528},"NCT06570811","Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients",[47],"2025-03-10","2025-03-30","2024-08-01",[15,30],[512],{"trials":530,"activeCount":68},[],{"trials":532,"activeCount":68},[],{"trials":534,"activeCount":68},[],{"intervention":536,"totalTrials":9,"cells":537},"Ascorbic Acid Injectable Product",{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":553,"PHASE4":555,"NA":557},{"trials":539,"activeCount":68},[],{"trials":541,"activeCount":68},[],{"trials":543,"activeCount":68},[544],{"nctId":545,"briefTitle":546,"status":116,"phases":547,"primaryCompletion":548,"completion":548,"start":549,"enrollment":218,"conditions":550,"interventions":552},"NCT04153487","Role of Ascorbic Acid Infusion in Critically Ill Patients With Transfusion Related Acute Lung Injury",[47],"2021-07-16","2019-11-30",[551],"Acute Lung Injury, Transfusion Related",[536],{"trials":554,"activeCount":68},[],{"trials":556,"activeCount":68},[],{"trials":558,"activeCount":68},[],{"intervention":560,"totalTrials":9,"cells":561},"Paclitaxel",{"EARLY_PHASE1":562,"PHASE1":564,"PHASE2":566,"PHASE3":576,"PHASE4":578,"NA":580},{"trials":563,"activeCount":68},[],{"trials":565,"activeCount":68},[],{"trials":567,"activeCount":68},[568],{"nctId":569,"briefTitle":570,"status":116,"phases":571,"primaryCompletion":572,"completion":572,"start":573,"enrollment":121,"conditions":574,"interventions":575},"NCT07307911","Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy",[47],"2026-02-10","2025-11-10",[15],[560],{"trials":577,"activeCount":68},[],{"trials":579,"activeCount":68},[],{"trials":581,"activeCount":68},[],{"intervention":583,"totalTrials":9,"cells":584},"Rosuvastatin 20 mg",{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":602,"PHASE4":604,"NA":606},{"trials":586,"activeCount":68},[],{"trials":588,"activeCount":68},[],{"trials":590,"activeCount":68},[591],{"nctId":592,"briefTitle":593,"status":116,"phases":594,"primaryCompletion":595,"completion":596,"start":597,"enrollment":61,"conditions":598,"interventions":600},"NCT05895123","Comparison Between the Effects of High Doses Statin on Ventricular Remodeling in STEMI Patients",[47],"2023-03-01","2023-04-01","2021-11-01",[599],"ST-segment Elevation Myocardial Infarction",[583,601],"Atorvastatin 40mg",{"trials":603,"activeCount":68},[],{"trials":605,"activeCount":68},[],{"trials":607,"activeCount":68},[],{"intervention":601,"totalTrials":9,"cells":609},{"EARLY_PHASE1":610,"PHASE1":612,"PHASE2":614,"PHASE3":620,"PHASE4":622,"NA":624},{"trials":611,"activeCount":68},[],{"trials":613,"activeCount":68},[],{"trials":615,"activeCount":68},[616],{"nctId":592,"briefTitle":593,"status":116,"phases":617,"primaryCompletion":595,"completion":596,"start":597,"enrollment":61,"conditions":618,"interventions":619},[47],[599],[583,601],{"trials":621,"activeCount":68},[],{"trials":623,"activeCount":68},[],{"trials":625,"activeCount":68},[],{"intervention":627,"totalTrials":9,"cells":628},"combined standard aerosolized doses of budesonide (0.5 mg\u002F2 mL) every 12 hours and ipratropium bromide (500\u002F2 mL) every eight hours for up to five days",{"EARLY_PHASE1":629,"PHASE1":631,"PHASE2":633,"PHASE3":646,"PHASE4":648,"NA":650},{"trials":630,"activeCount":68},[],{"trials":632,"activeCount":68},[],{"trials":634,"activeCount":68},[635],{"nctId":636,"briefTitle":637,"status":116,"phases":638,"primaryCompletion":639,"completion":639,"start":640,"enrollment":641,"conditions":642,"interventions":645},"NCT06657079","A Combination of an Inhaled Budesonide and Ipratropium in Patients at Risk of Developing ARDS",[46,47],"2025-01-01","2024-05-01",119,[643,644],"ARDS","Prevention and Control",[627],{"trials":647,"activeCount":68},[],{"trials":649,"activeCount":68},[],{"trials":651,"activeCount":68},[],{"intervention":653,"totalTrials":9,"cells":654},"Heparin",{"EARLY_PHASE1":655,"PHASE1":657,"PHASE2":659,"PHASE3":671,"PHASE4":673,"NA":675},{"trials":656,"activeCount":68},[],{"trials":658,"activeCount":68},[],{"trials":660,"activeCount":68},[661],{"nctId":662,"briefTitle":663,"status":116,"phases":664,"primaryCompletion":665,"completion":665,"start":666,"enrollment":218,"conditions":667,"interventions":670},"NCT04313790","Assessment of the Anti-inflammatory Effect of Heparin Infusion Versus Subcutaneous Injection in Septic Patients",[47],"2022-10-11","2020-08-29",[668,669],"Sepsis","Critical Illness",[653],{"trials":672,"activeCount":68},[],{"trials":674,"activeCount":68},[],{"trials":676,"activeCount":68},[],{"intervention":678,"totalTrials":9,"cells":679},"Celecoxib 100mg",{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":698,"PHASE4":700,"NA":702},{"trials":681,"activeCount":68},[],{"trials":683,"activeCount":68},[],{"trials":685,"activeCount":68},[686],{"nctId":687,"briefTitle":688,"status":116,"phases":689,"primaryCompletion":690,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":696},"NCT04374981","Effect of Pineapple Juice on the Pharmacokinetics of Celecoxib and Montelukast in Humans",[47],"2019-11-01","2019-12-01","2019-07-01",24,[695],"Food-drug Interaction",[678,697],"Montelukast 10mg",{"trials":699,"activeCount":68},[],{"trials":701,"activeCount":68},[],{"trials":703,"activeCount":68},[],{"intervention":697,"totalTrials":9,"cells":705},{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":716,"PHASE4":718,"NA":720},{"trials":707,"activeCount":68},[],{"trials":709,"activeCount":68},[],{"trials":711,"activeCount":68},[712],{"nctId":687,"briefTitle":688,"status":116,"phases":713,"primaryCompletion":690,"completion":691,"start":692,"enrollment":693,"conditions":714,"interventions":715},[47],[695],[678,697],{"trials":717,"activeCount":68},[],{"trials":719,"activeCount":68},[],{"trials":721,"activeCount":68},[],{"intervention":723,"totalTrials":8,"cells":724},"Hydrochlorothiazide",{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":731,"PHASE4":733,"NA":735},{"trials":726,"activeCount":68},[],{"trials":728,"activeCount":68},[],{"trials":730,"activeCount":68},[],{"trials":732,"activeCount":68},[],{"trials":734,"activeCount":68},[],{"trials":736,"activeCount":68},[737,748,758,767],{"nctId":738,"briefTitle":739,"status":116,"phases":740,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":744,"interventions":745},"NCT01858610","Drug Interaction Between Irbesartan and Hydrochlorothiazide",[50],"2013-04","2013-03",18,[24],[746,747,723],"Irbeasartan\u002Fhydrochlorothiazide","Irbesartan",{"nctId":749,"briefTitle":750,"status":116,"phases":751,"primaryCompletion":752,"completion":752,"start":753,"enrollment":693,"conditions":754,"interventions":755},"NCT01767259","Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide",[50],"2012-12","2012-10",[26],[756,757,723],"Valsartan\u002FHydrochlorothiazide","Valsartan",{"nctId":759,"briefTitle":760,"status":116,"phases":761,"primaryCompletion":742,"completion":742,"start":762,"enrollment":743,"conditions":763,"interventions":764},"NCT01858623","Pharmacokinetic Interactions of Losartan and Hydrochlorothiazide",[50],"2013-02",[26],[765,766,723],"Losartan\u002Fhydrochlorothiazide","Losartan",{"nctId":768,"briefTitle":769,"status":116,"phases":770,"primaryCompletion":752,"completion":752,"start":753,"enrollment":693,"conditions":771,"interventions":772},"NCT01767298","Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses)",[50],[26],[756,757,723],{"intervention":774,"totalTrials":22,"cells":775},"Empagliflozin 10 MG",{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":780,"PHASE3":782,"PHASE4":784,"NA":786},{"trials":777,"activeCount":68},[],{"trials":779,"activeCount":68},[],{"trials":781,"activeCount":68},[],{"trials":783,"activeCount":68},[],{"trials":785,"activeCount":68},[],{"trials":787,"activeCount":68},[788,797,808],{"nctId":789,"briefTitle":790,"status":116,"phases":791,"primaryCompletion":792,"completion":793,"start":794,"enrollment":121,"conditions":795,"interventions":796},"NCT07112274","Empagliflozin on Patients With Preserved Heart Failure",[50],"2025-06-30","2025-07-30","2022-10-01",[18],[774],{"nctId":798,"briefTitle":799,"status":116,"phases":800,"primaryCompletion":801,"completion":802,"start":803,"enrollment":804,"conditions":805,"interventions":806},"NCT06313008","Empagliflozin Versus Vildagliptin in CAD Patients With T2DM",[50],"2024-09-30","2024-10-10","2023-08-10",120,[21,32],[774,807],"Vildagliptin 50 MG",{"nctId":809,"briefTitle":810,"status":116,"phases":811,"primaryCompletion":812,"completion":813,"start":814,"enrollment":61,"conditions":815,"interventions":817},"NCT06065280","Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients",[50],"2024-12-01","2024-12-30","2022-11-01",[18,816],"Reduced Ejection Fraction Heart Failure",[774,818],"Dapagliflozin 10 MG",{"intervention":807,"totalTrials":22,"cells":820},{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":827,"PHASE4":829,"NA":835},{"trials":822,"activeCount":68},[],{"trials":824,"activeCount":68},[],{"trials":826,"activeCount":68},[],{"trials":828,"activeCount":68},[],{"trials":830,"activeCount":68},[831],{"nctId":168,"briefTitle":169,"status":116,"phases":832,"primaryCompletion":171,"completion":172,"start":173,"enrollment":61,"conditions":833,"interventions":834},[49],[21,175],[177,155,178],{"trials":836,"activeCount":68},[837,841],{"nctId":798,"briefTitle":799,"status":116,"phases":838,"primaryCompletion":801,"completion":802,"start":803,"enrollment":804,"conditions":839,"interventions":840},[50],[21,32],[774,807],{"nctId":842,"briefTitle":843,"status":116,"phases":844,"primaryCompletion":845,"completion":812,"start":794,"enrollment":482,"conditions":846,"interventions":847},"NCT06068686","Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients",[50],"2024-11-30",[32],[807,848],"Glimepiride 3 Mg Oral",{"intervention":757,"totalTrials":22,"cells":850},{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":857,"PHASE4":859,"NA":865},{"trials":852,"activeCount":68},[],{"trials":854,"activeCount":68},[],{"trials":856,"activeCount":68},[],{"trials":858,"activeCount":68},[],{"trials":860,"activeCount":68},[861],{"nctId":141,"briefTitle":142,"status":116,"phases":862,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":863,"interventions":864},[49],[149],[151,128],{"trials":866,"activeCount":68},[867,871],{"nctId":749,"briefTitle":750,"status":116,"phases":868,"primaryCompletion":752,"completion":752,"start":753,"enrollment":693,"conditions":869,"interventions":870},[50],[26],[756,757,723],{"nctId":768,"briefTitle":769,"status":116,"phases":872,"primaryCompletion":752,"completion":752,"start":753,"enrollment":693,"conditions":873,"interventions":874},[50],[26],[756,757,723],{"intervention":876,"totalTrials":11,"cells":877},"polymorphism analysis",{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":884,"PHASE4":886,"NA":888},{"trials":879,"activeCount":68},[],{"trials":881,"activeCount":68},[],{"trials":883,"activeCount":68},[],{"trials":885,"activeCount":68},[],{"trials":887,"activeCount":68},[],{"trials":889,"activeCount":68},[890,899],{"nctId":891,"briefTitle":892,"status":396,"phases":893,"primaryCompletion":354,"completion":354,"start":894,"enrollment":95,"conditions":895,"interventions":897},"NCT04654195","Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient",[],"2020-12-01",[896],"Breast Cancer Patients",[876,898],"Doxorubicin-Cyclophosphamide regimen",{"nctId":900,"briefTitle":901,"status":396,"phases":902,"primaryCompletion":903,"completion":904,"start":905,"enrollment":95,"conditions":906,"interventions":907},"NCT04581967","Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients",[],"2020-12-15","2021-01-15","2020-10-15",[896],[876,898],{"intervention":898,"totalTrials":11,"cells":909},{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":916,"PHASE4":918,"NA":920},{"trials":911,"activeCount":68},[],{"trials":913,"activeCount":68},[],{"trials":915,"activeCount":68},[],{"trials":917,"activeCount":68},[],{"trials":919,"activeCount":68},[],{"trials":921,"activeCount":68},[922,926],{"nctId":891,"briefTitle":892,"status":396,"phases":923,"primaryCompletion":354,"completion":354,"start":894,"enrollment":95,"conditions":924,"interventions":925},[],[896],[876,898],{"nctId":900,"briefTitle":901,"status":396,"phases":927,"primaryCompletion":903,"completion":904,"start":905,"enrollment":95,"conditions":928,"interventions":929},[],[896],[876,898],{"intervention":756,"totalTrials":11,"cells":931},{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":938,"PHASE4":940,"NA":942},{"trials":933,"activeCount":68},[],{"trials":935,"activeCount":68},[],{"trials":937,"activeCount":68},[],{"trials":939,"activeCount":68},[],{"trials":941,"activeCount":68},[],{"trials":943,"activeCount":68},[944,948],{"nctId":749,"briefTitle":750,"status":116,"phases":945,"primaryCompletion":752,"completion":752,"start":753,"enrollment":693,"conditions":946,"interventions":947},[50],[26],[756,757,723],{"nctId":768,"briefTitle":769,"status":116,"phases":949,"primaryCompletion":752,"completion":752,"start":753,"enrollment":693,"conditions":950,"interventions":951},[50],[26],[756,757,723],{"intervention":818,"totalTrials":11,"cells":953},{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":972,"PHASE4":974,"NA":976},{"trials":955,"activeCount":68},[],{"trials":957,"activeCount":68},[],{"trials":959,"activeCount":68},[960],{"nctId":961,"briefTitle":962,"status":396,"phases":963,"primaryCompletion":964,"completion":965,"start":966,"enrollment":357,"conditions":967,"interventions":971},"NCT04304560","Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial",[47],"2021-03","2021-04","2020-03",[968,969,970],"Heart Failure With Reduced Ejection Fraction (HFrEF)","Diabete Type 2","Cardiomyopathies",[818],{"trials":973,"activeCount":68},[],{"trials":975,"activeCount":68},[],{"trials":977,"activeCount":68},[978],{"nctId":809,"briefTitle":810,"status":116,"phases":979,"primaryCompletion":812,"completion":813,"start":814,"enrollment":61,"conditions":980,"interventions":981},[50],[18,816],[774,818],{"intervention":983,"totalTrials":9,"cells":984},"Glimepiride",{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":991,"PHASE4":993,"NA":995},{"trials":986,"activeCount":68},[],{"trials":988,"activeCount":68},[],{"trials":990,"activeCount":68},[],{"trials":992,"activeCount":68},[],{"trials":994,"activeCount":68},[],{"trials":996,"activeCount":68},[997],{"nctId":998,"briefTitle":999,"status":116,"phases":1000,"primaryCompletion":456,"completion":1001,"start":1002,"enrollment":482,"conditions":1003,"interventions":1005},"NCT03917940","Omega 3 Fatty Acids on Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride",[50],"2020-05-10","2019-01-31",[1004],"Diabetic Patients",[983],{"intervention":1007,"totalTrials":9,"cells":1008},"Dexmedetomidine Injectable Solution",{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1013,"PHASE3":1015,"PHASE4":1017,"NA":1019},{"trials":1010,"activeCount":68},[],{"trials":1012,"activeCount":68},[],{"trials":1014,"activeCount":68},[],{"trials":1016,"activeCount":68},[],{"trials":1018,"activeCount":68},[],{"trials":1020,"activeCount":68},[1021],{"nctId":1022,"briefTitle":1023,"status":116,"phases":1024,"primaryCompletion":1025,"completion":1025,"start":1026,"enrollment":357,"conditions":1027,"interventions":1029},"NCT06661980","Dexmedetomidine on Brain Injury Patients",[50],"2025-10-28","2024-10-15",[1028],"Brain Injuries",[1007],{"intervention":1031,"totalTrials":9,"cells":1032},"Sacubitril-valsartan",{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1039,"PHASE4":1041,"NA":1043},{"trials":1034,"activeCount":68},[],{"trials":1036,"activeCount":68},[],{"trials":1038,"activeCount":68},[],{"trials":1040,"activeCount":68},[],{"trials":1042,"activeCount":68},[],{"trials":1044,"activeCount":68},[1045],{"nctId":1046,"briefTitle":1047,"status":116,"phases":1048,"primaryCompletion":1049,"completion":1050,"start":1051,"enrollment":357,"conditions":1052,"interventions":1053},"NCT07341893","Sacubitril-valsartan in Patients With Heart Failure.",[50],"2026-03-01","2026-03-30","2025-08-01",[18],[1031,1054],"standard treatment of heart failure",{"intervention":1054,"totalTrials":9,"cells":1056},{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1063,"PHASE4":1065,"NA":1067},{"trials":1058,"activeCount":68},[],{"trials":1060,"activeCount":68},[],{"trials":1062,"activeCount":68},[],{"trials":1064,"activeCount":68},[],{"trials":1066,"activeCount":68},[],{"trials":1068,"activeCount":68},[1069],{"nctId":1046,"briefTitle":1047,"status":116,"phases":1070,"primaryCompletion":1049,"completion":1050,"start":1051,"enrollment":357,"conditions":1071,"interventions":1072},[50],[18],[1031,1054],{"intervention":1074,"totalTrials":9,"cells":1075},"Ciprofloxacin",{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1080,"PHASE3":1082,"PHASE4":1084,"NA":1086},{"trials":1077,"activeCount":68},[],{"trials":1079,"activeCount":68},[],{"trials":1081,"activeCount":68},[],{"trials":1083,"activeCount":68},[],{"trials":1085,"activeCount":68},[],{"trials":1087,"activeCount":68},[1088],{"nctId":1089,"briefTitle":1090,"status":116,"phases":1091,"primaryCompletion":1092,"completion":1093,"start":423,"enrollment":1094,"conditions":1095,"interventions":1097},"NCT05916105","Ciprofloxacin Utilization and Adverse Events Occurrence in Community Pharmacy Setting",[],"2022-02-28","2022-03-01",151,[1096],"Ciprofloxacin Adverse Reaction",[1074],{"intervention":1099,"totalTrials":9,"cells":1100},"Alpha Lipoic Acid 600 MG Oral",{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1105,"PHASE3":1107,"PHASE4":1109,"NA":1111},{"trials":1102,"activeCount":68},[],{"trials":1104,"activeCount":68},[],{"trials":1106,"activeCount":68},[],{"trials":1108,"activeCount":68},[],{"trials":1110,"activeCount":68},[],{"trials":1112,"activeCount":68},[1113],{"nctId":1114,"briefTitle":1115,"status":116,"phases":1116,"primaryCompletion":1117,"completion":1118,"start":595,"enrollment":357,"conditions":1119,"interventions":1122},"NCT06056687","Alpha-lipoic Acid in Diabetic Patients With Ischemic Cardiomyopathy",[50],"2024-01-31","2024-02-01",[1120,1121],"Ischemic Cardiomyopathy","Diabetes Mellitus",[1099],{"intervention":1124,"totalTrials":9,"cells":1125},"AC protocol",{"EARLY_PHASE1":1126,"PHASE1":1128,"PHASE2":1130,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1127,"activeCount":68},[],{"trials":1129,"activeCount":68},[],{"trials":1131,"activeCount":68},[],{"trials":1133,"activeCount":68},[],{"trials":1135,"activeCount":68},[],{"trials":1137,"activeCount":68},[1138],{"nctId":1139,"briefTitle":1140,"status":116,"phases":1141,"primaryCompletion":845,"completion":812,"start":595,"enrollment":121,"conditions":1142,"interventions":1144},"NCT05959889","Effect of Montelukast on Doxorubicin Induced Cardiotoxicity in Breast Cancer",[50],[15,1143],"Doxorubicin Induced Cardiotoxicity",[1124,1145],"Montelukast",{"intervention":1145,"totalTrials":9,"cells":1147},{"EARLY_PHASE1":1148,"PHASE1":1150,"PHASE2":1152,"PHASE3":1154,"PHASE4":1156,"NA":1158},{"trials":1149,"activeCount":68},[],{"trials":1151,"activeCount":68},[],{"trials":1153,"activeCount":68},[],{"trials":1155,"activeCount":68},[],{"trials":1157,"activeCount":68},[],{"trials":1159,"activeCount":68},[1160],{"nctId":1139,"briefTitle":1140,"status":116,"phases":1161,"primaryCompletion":845,"completion":812,"start":595,"enrollment":121,"conditions":1162,"interventions":1163},[50],[15,1143],[1124,1145],{"intervention":746,"totalTrials":9,"cells":1165},{"EARLY_PHASE1":1166,"PHASE1":1168,"PHASE2":1170,"PHASE3":1172,"PHASE4":1174,"NA":1176},{"trials":1167,"activeCount":68},[],{"trials":1169,"activeCount":68},[],{"trials":1171,"activeCount":68},[],{"trials":1173,"activeCount":68},[],{"trials":1175,"activeCount":68},[],{"trials":1177,"activeCount":68},[1178],{"nctId":738,"briefTitle":739,"status":116,"phases":1179,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":1180,"interventions":1181},[50],[24],[746,747,723],{"intervention":747,"totalTrials":9,"cells":1183},{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1190,"PHASE4":1192,"NA":1194},{"trials":1185,"activeCount":68},[],{"trials":1187,"activeCount":68},[],{"trials":1189,"activeCount":68},[],{"trials":1191,"activeCount":68},[],{"trials":1193,"activeCount":68},[],{"trials":1195,"activeCount":68},[1196],{"nctId":738,"briefTitle":739,"status":116,"phases":1197,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":1198,"interventions":1199},[50],[24],[746,747,723],{"intervention":1201,"totalTrials":9,"cells":1202},"CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study",{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1209,"PHASE4":1211,"NA":1213},{"trials":1204,"activeCount":68},[],{"trials":1206,"activeCount":68},[],{"trials":1208,"activeCount":68},[],{"trials":1210,"activeCount":68},[],{"trials":1212,"activeCount":68},[],{"trials":1214,"activeCount":68},[1215],{"nctId":1216,"briefTitle":1217,"status":116,"phases":1218,"primaryCompletion":1219,"completion":801,"start":595,"enrollment":1220,"conditions":1221,"interventions":1223},"NCT05911724","Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.",[],"2024-09-20",180,[1222,18],"Stable Angina",[1201,1224],"HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study",{"intervention":1224,"totalTrials":9,"cells":1226},{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1233,"PHASE4":1235,"NA":1237},{"trials":1228,"activeCount":68},[],{"trials":1230,"activeCount":68},[],{"trials":1232,"activeCount":68},[],{"trials":1234,"activeCount":68},[],{"trials":1236,"activeCount":68},[],{"trials":1238,"activeCount":68},[1239],{"nctId":1216,"briefTitle":1217,"status":116,"phases":1240,"primaryCompletion":1219,"completion":801,"start":595,"enrollment":1220,"conditions":1241,"interventions":1242},[],[1222,18],[1201,1224],{"intervention":848,"totalTrials":9,"cells":1244},{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1249,"PHASE3":1251,"PHASE4":1253,"NA":1255},{"trials":1246,"activeCount":68},[],{"trials":1248,"activeCount":68},[],{"trials":1250,"activeCount":68},[],{"trials":1252,"activeCount":68},[],{"trials":1254,"activeCount":68},[],{"trials":1256,"activeCount":68},[1257],{"nctId":842,"briefTitle":843,"status":116,"phases":1258,"primaryCompletion":845,"completion":812,"start":794,"enrollment":482,"conditions":1259,"interventions":1260},[50],[32],[807,848],{"intervention":1262,"totalTrials":9,"cells":1263},"Clindamycin 600 mg",{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1270,"PHASE4":1272,"NA":1274},{"trials":1265,"activeCount":68},[],{"trials":1267,"activeCount":68},[],{"trials":1269,"activeCount":68},[],{"trials":1271,"activeCount":68},[],{"trials":1273,"activeCount":68},[],{"trials":1275,"activeCount":68},[1276],{"nctId":1277,"briefTitle":1278,"status":116,"phases":1279,"primaryCompletion":1280,"completion":1281,"start":595,"enrollment":1282,"conditions":1283,"interventions":1286},"NCT06068673","The Potential Impact of Clindamycin on Neurosurgery Patients.",[50],"2023-12-01","2023-12-30",44,[1284,1285],"Neurologic Complication","Neurosurgery",[1262,1287],"standard regimen",{"intervention":1287,"totalTrials":9,"cells":1289},{"EARLY_PHASE1":1290,"PHASE1":1292,"PHASE2":1294,"PHASE3":1296,"PHASE4":1298,"NA":1300},{"trials":1291,"activeCount":68},[],{"trials":1293,"activeCount":68},[],{"trials":1295,"activeCount":68},[],{"trials":1297,"activeCount":68},[],{"trials":1299,"activeCount":68},[],{"trials":1301,"activeCount":68},[1302],{"nctId":1277,"briefTitle":1278,"status":116,"phases":1303,"primaryCompletion":1280,"completion":1281,"start":595,"enrollment":1282,"conditions":1304,"interventions":1305},[50],[1284,1285],[1262,1287],{"intervention":1307,"totalTrials":9,"cells":1308},"fexofenadine",{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1315,"PHASE4":1317,"NA":1319},{"trials":1310,"activeCount":68},[],{"trials":1312,"activeCount":68},[],{"trials":1314,"activeCount":68},[],{"trials":1316,"activeCount":68},[],{"trials":1318,"activeCount":68},[],{"trials":1320,"activeCount":68},[1321],{"nctId":1322,"briefTitle":1323,"status":116,"phases":1324,"primaryCompletion":1325,"completion":1325,"start":752,"enrollment":1326,"conditions":1327,"interventions":1328},"NCT01767272","Dose Proportionality of Fexofenadine in Healthy Human Egyptian Volunteers",[50],"2013-01",25,[24],[1307],{"intervention":765,"totalTrials":9,"cells":1330},{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1337,"PHASE4":1339,"NA":1341},{"trials":1332,"activeCount":68},[],{"trials":1334,"activeCount":68},[],{"trials":1336,"activeCount":68},[],{"trials":1338,"activeCount":68},[],{"trials":1340,"activeCount":68},[],{"trials":1342,"activeCount":68},[1343],{"nctId":759,"briefTitle":760,"status":116,"phases":1344,"primaryCompletion":742,"completion":742,"start":762,"enrollment":743,"conditions":1345,"interventions":1346},[50],[26],[765,766,723],{"intervention":766,"totalTrials":9,"cells":1348},{"EARLY_PHASE1":1349,"PHASE1":1351,"PHASE2":1353,"PHASE3":1355,"PHASE4":1357,"NA":1359},{"trials":1350,"activeCount":68},[],{"trials":1352,"activeCount":68},[],{"trials":1354,"activeCount":68},[],{"trials":1356,"activeCount":68},[],{"trials":1358,"activeCount":68},[],{"trials":1360,"activeCount":68},[1361],{"nctId":759,"briefTitle":760,"status":116,"phases":1362,"primaryCompletion":742,"completion":742,"start":762,"enrollment":743,"conditions":1363,"interventions":1364},[50],[26],[765,766,723],{"intervention":1366,"totalTrials":9,"cells":1367},"600 mg linezolid",{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1374,"PHASE4":1376,"NA":1378},{"trials":1369,"activeCount":68},[],{"trials":1371,"activeCount":68},[],{"trials":1373,"activeCount":68},[],{"trials":1375,"activeCount":68},[],{"trials":1377,"activeCount":68},[],{"trials":1379,"activeCount":68},[1380],{"nctId":1381,"briefTitle":1382,"status":116,"phases":1383,"primaryCompletion":1384,"completion":1384,"start":1385,"enrollment":743,"conditions":1386,"interventions":1389},"NCT02087566","Linezolid Pharmacokinetics In Patients With Impaired Renal Function (PPT6)",[50],"2014-01","2013-10",[1387,1388],"Renal Failure","Impaired Renal Function",[1366],{"intervention":1391,"totalTrials":9,"cells":1392},"Fenofibrate 160mg",{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1399,"PHASE4":1401,"NA":1403},{"trials":1394,"activeCount":68},[],{"trials":1396,"activeCount":68},[],{"trials":1398,"activeCount":68},[],{"trials":1400,"activeCount":68},[],{"trials":1402,"activeCount":68},[],{"trials":1404,"activeCount":68},[1405],{"nctId":1406,"briefTitle":1407,"status":116,"phases":1408,"primaryCompletion":526,"completion":1409,"start":1410,"enrollment":121,"conditions":1411,"interventions":1412},"NCT05813145","Fenofibrate Role in Breast Cancer Patients",[50],"2024-08-05","2023-01-01",[15],[1391],{"intervention":1414,"totalTrials":9,"cells":1415},"Dapagliflozin 5Mg Tab",{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1422,"PHASE4":1424,"NA":1426},{"trials":1417,"activeCount":68},[],{"trials":1419,"activeCount":68},[],{"trials":1421,"activeCount":68},[],{"trials":1423,"activeCount":68},[],{"trials":1425,"activeCount":68},[],{"trials":1427,"activeCount":68},[1428],{"nctId":1429,"briefTitle":1430,"status":116,"phases":1431,"primaryCompletion":1432,"completion":1433,"start":894,"enrollment":357,"conditions":1434,"interventions":1435},"NCT04240171","Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus",[],"2022-01-30","2022-01-31",[175],[1414,1436],"Glimepiride 4Mg Tab",{"intervention":1436,"totalTrials":9,"cells":1438},{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1445,"PHASE4":1447,"NA":1449},{"trials":1440,"activeCount":68},[],{"trials":1442,"activeCount":68},[],{"trials":1444,"activeCount":68},[],{"trials":1446,"activeCount":68},[],{"trials":1448,"activeCount":68},[],{"trials":1450,"activeCount":68},[1451],{"nctId":1429,"briefTitle":1430,"status":116,"phases":1452,"primaryCompletion":1432,"completion":1433,"start":894,"enrollment":357,"conditions":1453,"interventions":1454},[],[175],[1414,1436],{"intervention":1456,"totalTrials":9,"cells":1457},"Sulpiride",{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1462,"PHASE3":1464,"PHASE4":1466,"NA":1468},{"trials":1459,"activeCount":68},[],{"trials":1461,"activeCount":68},[],{"trials":1463,"activeCount":68},[],{"trials":1465,"activeCount":68},[],{"trials":1467,"activeCount":68},[],{"trials":1469,"activeCount":68},[1470],{"nctId":1471,"briefTitle":1472,"status":116,"phases":1473,"primaryCompletion":1325,"completion":1325,"start":1325,"enrollment":1474,"conditions":1475,"interventions":1476},"NCT01777685","Therapeutic Drug Monitoring and Pharmacokinetic Compartmental Analysis of Sulpiride After Oral Administration to Healthy Volunteers",[50],16,[24],[1456],{"intervention":1478,"totalTrials":9,"cells":1479},"Sorafenib",{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1486,"PHASE4":1488,"NA":1490},{"trials":1481,"activeCount":68},[],{"trials":1483,"activeCount":68},[],{"trials":1485,"activeCount":68},[],{"trials":1487,"activeCount":68},[],{"trials":1489,"activeCount":68},[],{"trials":1491,"activeCount":68},[1492],{"nctId":1493,"briefTitle":1494,"status":116,"phases":1495,"primaryCompletion":1496,"completion":1497,"start":1498,"enrollment":95,"conditions":1499,"interventions":1501},"NCT06030895","Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.",[50],"2024-02-21","2024-03-01","2022-12-12",[1500],"Hepatocellular Carcinoma",[1478]]